Dr. Steven Chamow is presenting at two virtual conferences this week, the 11th Annual World Bispecific Conference and BioProcess International Conference. Both presentations are available for viewing on the Chamow & Associates’ Conferences page.
On September, 22, 2020, Dr. Chamow led a workshop on, “The Process of CDMO Selection for Bispecific Antibody Development: Matching Capabilities to Need” at the 11th Annual World Bispecific Conference. In this workshop, he outlined best practices to identify and select a CDMO for the development and clinical manufacture of bispecific antibodies.
On September 23, 2020, Dr. Chamow presented, “Capture of CH1-Containing Bispecific Antibodies: An Alternative to Protein A” at the BioProcess International Conference. Bispecific antibodies are an important and growing class of protein therapeutics. They are designed to recognize and bind to two different antigens, often for the purpose of retargeting immune effector cells to kill cancer cells. Dr. Chamow and his team published this work in the May 2020 issue of BioProcess International. For further reading, please click here to view the article.